XML 21 R12.htm IDEA: XBRL DOCUMENT v3.22.2.2
Supplemental Balance Sheet Information
9 Months Ended
Sep. 30, 2022
Balance Sheet Related Disclosures [Abstract]  
Supplemental Balance Sheet Information

5. Supplemental Balance Sheet Information

Prepaid expenses and other current assets

Prepaid expenses and other current assets consisted of the following:

 

 

September 30,
2022

 

 

December 31,
2021

 

Prepaid research and development expenses

 

$

4,112

 

 

$

4,496

 

Tax incentive refund

 

 

2,984

 

 

 

2,697

 

Prepaid insurance

 

 

1,484

 

 

 

112

 

Other current assets

 

 

765

 

 

 

1,698

 

Prepaid compensation benefits

 

 

428

 

 

 

575

 

Prepaid expenses and other current assets

 

$

9,773

 

 

$

9,578

 

 

 

Property and equipment, net

Property and equipment, net consisted of the following:

 

 

 

September 30,
2022

 

 

December 31,
2021

 

Laboratory and office equipment

 

$

5,947

 

 

$

6,162

 

Leasehold improvements

 

 

629

 

 

 

1,635

 

Computer equipment

 

 

102

 

 

 

149

 

 

 

 

6,678

 

 

 

7,946

 

Less: Accumulated depreciation and amortization

 

 

(3,455

)

 

 

(3,820

)

Property and equipment, net

 

$

3,223

 

 

$

4,126

 

 

 

Depreciation and amortization expense was $336 and $374, respectively, for the three months ended September 30, 2022 and 2021. Depreciation and amortization expense was $1,105 and $963, respectively, for the nine months ended September 30, 2022 and 2021.

Restricted cash

As of September 30, 2022 and December 31, 2021, the Company had restricted cash of $492. $283 consists of cash used to secure a letter of credit for the benefit of the landlord in connection with the Company’s lease agreements. The cash will be restricted until the termination or modification of the lease arrangement. $209 consists of cash to be released within 60 days following the termination of a lease arrangement that was terminated on September 23, 2022.

 

Accrued expenses and other current liabilities

Accrued expenses and other current liabilities consisted of the following:

 

 

September 30,
2022

 

 

December 31,
2021

 

Research and development expenses

 

$

7,645

 

 

$

8,882

 

Compensation and benefit costs

 

 

5,402

 

 

 

5,579

 

Consulting and professional fees

 

 

871

 

 

 

999

 

Other liabilities

 

 

409

 

 

 

178

 

Accrued expenses and other current liabilities

 

$

14,327

 

 

$

15,638